Effect of indomethacin plus ranitidine in advanced melanoma patients on high-dose interleukin-2.
Preclinical models of advanced melanoma have shown that chronic indomethacin therapy combined with interleukin 2 (IL-2) can eradicate experimental metastases. A phase II trial was done in patients with advanced melanoma. Indomethacin and ranitidine were begun at least one week before IL-2. Of the objective responses in 3 patients, 2 were achieved on ranitidine and indomethacin alone, before start of IL-2. Indomethacin and ranitidine may be responsible for some responses in melanoma patients previously attributed to IL-2.
Department of Medical Oncology, London Regional Cancer Centre, Canada.
W C
WC
Mertens
V H
VH
Bramwell
F
F
Gwadry-Sridhar
W
W
Romano
D
D
Banerjee
P K
PK
Lala
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007213:Indomethacin / Q000008:administration & dosage*; D007376:Interleukin-2 / Q000008:administration & dosage; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D008875:Middle Aged; D011899:Ranitidine / Q000008:administration & dosage*
D007376:Interleukin-2; D011899:Ranitidine; D007213:Indomethacin